Google Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? Google Inc trades at $347.86 (market cap $4.24T), while Roivant Sciences Ltd. Common Shares trades at $35.44 (market cap $24.72B). The key difference: Google Inc is far larger — about 171.5× Roivant Sciences Ltd. Common Shares's market cap, and Google Inc pays a 0.26% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| GOOG | ROIV | |
|---|---|---|
Market Cap | $4.24T | $24.72B |
Volume | 13,937,902 | 6,279,442 |
Sector | Media | Health |
52-Week High | $399.06 | $41.81 |
52-Week Low | $237.49 | $16.04 |
Typical Hold Time | 137 Days | 1 Days |
Enterprise Value | $4.13T | $20.99B |
Dividend Yield | 0.26% | — |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $344.86, down 0.72% on the day, with strong technical support at $342 and resistance at $348. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income of $132.17B, achieving consistent earnings beats in recent quarters. Analyst sentiment remains overwhelmingly positive with 87% buy ratings and a $435.24 consensus price target, representing 26% upside potential.
The outlook remains favorable given Alphabet's dominant market position and AI leadership, though investors should monitor elevated capital expenditures and potential regulatory risks. The stock's current valuation at 17.3x P/E appears reasonable relative to growth prospects, with upcoming Q3 earnings on October 31, 2026, serving as the next key catalyst.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →